泼尼松龙新型靶向脂质体制剂对嘌呤霉素氨基核苷肾病的疗效  

Therapeutic effect of a new liposome-prednisolone on the puromycin aminonucleoside nephropathy in rats

作　　者：刘丽华[1] 欧周罗[1] 朱春芳[1] 王磊[1] 

机构地区：[1]复旦大学上海医学院生物化学与分子生物学系

出　　处：《药学实践杂志》2004年第3期138-140,共3页Journal of Pharmaceutical Practice

摘　　要：目的 :观察肾小球向性泼尼松龙新型靶向脂质体制剂对嘌呤霉素氨基核苷性肾病的治疗作用。方法 :选用雄性Wistar大鼠 ,按照嘌呤霉素氨基核苷 ( puromycinaminoneucleoside ,PAN) 4 .0mg/ 10 0 g体重的剂量建立大鼠PAN模型 ,以泼尼松龙 ( prednisolone ,PRED) 2mg/ 10 0 g体重及泼尼松龙新型靶向脂质体制剂(liposome prednisolone ,Lipo PRED) 1.5mg/ 10 0 g体重的剂量进行治疗 ,观察尿蛋白的排出量、肾组织白细胞浸润等。结果 :泼尼松龙新型靶向脂质体制剂治疗组尿蛋白排泄量显著性降低 ,肾组织中白细胞浸润减少 ,其作用优于泼尼松龙治疗组结论 :泼尼松龙新型靶向脂质体制剂可显著性抑制PAN模型的尿蛋白排泄量和急性期肾间质白细胞浸润。Objective: To observe the effect of a novel liposome prednisolone on puromycin aminonucleoside (PAN) nephropathy model in rats. Methods:160～180g BW male Wistar rats were used in this experiment. The rats were given a single injection of PAN at the dose of 4mg/100g BW through right jugular vein to establish the nephrotic syndrome (NS) model. The free prednisolone (PRED) treated group were given (i.p.) the free prednisolone at the dose of 2.0mg/100g BW and the liposome prednisolone (Lipo PRED) treated group were given (i.v.) the liposome prednisolone at the dose of 1.5mg/100g BW. Urinary protein excretion examined with the biuret method and the monocyte/macrophage, CD 4 + T cells and CD 8 + T cells were analyzed by immunohistochemistry. Results:The proteinuria of the Lipo PRED treated group reduced; the infiltration of monocyte/macrophages, CD 4 +T cells and CD 8 +T cells in the glomeruli and interstitium also remarkably weakened. Conclusion:The liposome prednisolone can remarkably reduce the proteinuria excretion and leukocyte infiltration both in the glomeruli and tubulointerstitium in the PAN model.

关 键 词：泼尼松龙 泼尼松龙脂质体制剂 嘌呤霉素氨基核苷 蛋白尿 

分 类 号：R977.11[医药卫生—药品] R961[医药卫生—药学]